Cargando…

Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City

BACKGROUND: The social determinants of health that influence steps in the entire Hepatitis C Virus (HCV) treatment cascade must be identified to achieve HCV elimination goals. This project aimed to evaluate the association of these factors with HCV treatment completion and return for sustained virol...

Descripción completa

Detalles Bibliográficos
Autores principales: Ziff, Jacob, Vu, Trang, Dvir, Danielle, Riazi, Farah, Toribio, Wilma, Oster, Scott, Sigel, Keith, Weiss, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010955/
https://www.ncbi.nlm.nih.gov/pubmed/33789691
http://dx.doi.org/10.1186/s12954-021-00486-4
_version_ 1783673157300781056
author Ziff, Jacob
Vu, Trang
Dvir, Danielle
Riazi, Farah
Toribio, Wilma
Oster, Scott
Sigel, Keith
Weiss, Jeffrey
author_facet Ziff, Jacob
Vu, Trang
Dvir, Danielle
Riazi, Farah
Toribio, Wilma
Oster, Scott
Sigel, Keith
Weiss, Jeffrey
author_sort Ziff, Jacob
collection PubMed
description BACKGROUND: The social determinants of health that influence steps in the entire Hepatitis C Virus (HCV) treatment cascade must be identified to achieve HCV elimination goals. This project aimed to evaluate the association of these factors with HCV treatment completion and return for sustained virologic response (SVR) testing. METHODS: We used retrospective cohort data from our primary care-based HCV treatment program that provides comprehensive harm reduction care to those who use or formerly used drugs. Among persons who began direct-acting antiviral HCV treatment between December 2014 and March 2018, we identified two outcomes: HCV treatment completion and return for SVR assessment 12 weeks after treatment end. Several predictors were ascertained including sociodemographic information, substance use, psychiatric symptoms and history, housing instability, and HCV treatment regimen. We then evaluated associations between predictors and outcomes using univariate and multivariable statistical methods. RESULTS: From a cohort of 329 patients treated in an urban primary care center, multivariable analysis identified housing instability as a single significant predictor for HCV treatment completion (odds ratio [OR]: 0.3; 95% confidence interval [CI]: 0.1–0.9). Among patients completing treatment, 226 (75%) returned for SVR assessment; the sole predictor of this outcome was Medicaid as primary insurance (compared to other insurances; OR 0.3; 0.1–0.7). CONCLUSIONS: Innovative strategies to help unstably housed persons complete HCV treatment are urgently needed in order to reach HCV elimination targets. Educational and motivational strategies should be developed to promote individuals with Medicaid in particular to return for SVR viral load testing, a critical post-treatment component of the HCV treatment cascade. Trial registration Not applicable.
format Online
Article
Text
id pubmed-8010955
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80109552021-03-31 Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City Ziff, Jacob Vu, Trang Dvir, Danielle Riazi, Farah Toribio, Wilma Oster, Scott Sigel, Keith Weiss, Jeffrey Harm Reduct J Research BACKGROUND: The social determinants of health that influence steps in the entire Hepatitis C Virus (HCV) treatment cascade must be identified to achieve HCV elimination goals. This project aimed to evaluate the association of these factors with HCV treatment completion and return for sustained virologic response (SVR) testing. METHODS: We used retrospective cohort data from our primary care-based HCV treatment program that provides comprehensive harm reduction care to those who use or formerly used drugs. Among persons who began direct-acting antiviral HCV treatment between December 2014 and March 2018, we identified two outcomes: HCV treatment completion and return for SVR assessment 12 weeks after treatment end. Several predictors were ascertained including sociodemographic information, substance use, psychiatric symptoms and history, housing instability, and HCV treatment regimen. We then evaluated associations between predictors and outcomes using univariate and multivariable statistical methods. RESULTS: From a cohort of 329 patients treated in an urban primary care center, multivariable analysis identified housing instability as a single significant predictor for HCV treatment completion (odds ratio [OR]: 0.3; 95% confidence interval [CI]: 0.1–0.9). Among patients completing treatment, 226 (75%) returned for SVR assessment; the sole predictor of this outcome was Medicaid as primary insurance (compared to other insurances; OR 0.3; 0.1–0.7). CONCLUSIONS: Innovative strategies to help unstably housed persons complete HCV treatment are urgently needed in order to reach HCV elimination targets. Educational and motivational strategies should be developed to promote individuals with Medicaid in particular to return for SVR viral load testing, a critical post-treatment component of the HCV treatment cascade. Trial registration Not applicable. BioMed Central 2021-03-31 /pmc/articles/PMC8010955/ /pubmed/33789691 http://dx.doi.org/10.1186/s12954-021-00486-4 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ziff, Jacob
Vu, Trang
Dvir, Danielle
Riazi, Farah
Toribio, Wilma
Oster, Scott
Sigel, Keith
Weiss, Jeffrey
Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
title Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
title_full Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
title_fullStr Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
title_full_unstemmed Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
title_short Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
title_sort predictors of hepatitis c treatment outcomes in a harm reduction-focused primary care program in new york city
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010955/
https://www.ncbi.nlm.nih.gov/pubmed/33789691
http://dx.doi.org/10.1186/s12954-021-00486-4
work_keys_str_mv AT ziffjacob predictorsofhepatitisctreatmentoutcomesinaharmreductionfocusedprimarycareprograminnewyorkcity
AT vutrang predictorsofhepatitisctreatmentoutcomesinaharmreductionfocusedprimarycareprograminnewyorkcity
AT dvirdanielle predictorsofhepatitisctreatmentoutcomesinaharmreductionfocusedprimarycareprograminnewyorkcity
AT riazifarah predictorsofhepatitisctreatmentoutcomesinaharmreductionfocusedprimarycareprograminnewyorkcity
AT toribiowilma predictorsofhepatitisctreatmentoutcomesinaharmreductionfocusedprimarycareprograminnewyorkcity
AT osterscott predictorsofhepatitisctreatmentoutcomesinaharmreductionfocusedprimarycareprograminnewyorkcity
AT sigelkeith predictorsofhepatitisctreatmentoutcomesinaharmreductionfocusedprimarycareprograminnewyorkcity
AT weissjeffrey predictorsofhepatitisctreatmentoutcomesinaharmreductionfocusedprimarycareprograminnewyorkcity